Orexo AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
139,689.00
25,007.00
180,600.00
51,700.00
57,400.00
95,800
Depreciation, Depletion & Amortization
-
12,527.00
80,700.00
25,000.00
20,800.00
20,800
Other Funds
77,825.00
23,060.00
52,700.00
9,200.00
32,100.00
11,300
Funds from Operations
61,864.00
35,540.00
47,200.00
67,500.00
110,300.00
127,900
Changes in Working Capital
201,337.00
451,760.00
62,000.00
88,700.00
36,300.00
114,100
Net Operating Cash Flow
263,201.00
487,300.00
109,200.00
156,200.00
146,600.00
242,000
Capital Expenditures
107,505.00
71,723.00
4,000.00
1,400.00
1,600.00
Sale of Fixed Assets & Businesses
-
24.00
21,800.00
6,900.00
-
Net Investing Cash Flow
107,505.00
71,699.00
17,800.00
5,500.00
1,600.00
Issuance/Reduction of Debt, Net
231,641.00
397,645.00
1,200.00
92,800.00
85,500.00
Net Financing Cash Flow
251,056.00
739,365.00
2,600.00
90,600.00
85,400.00
Net Change in Cash
122,424.00
178,837.00
86,300.00
84,300.00
45,500.00
Free Cash Flow
370,706.00
559,023.00
109,500.00
155,100.00
145,500.00
Change in Capital Stock
19,415.00
341,720.00
3,800.00
2,200.00
100.00
Exchange Rate Effect
2,774.00
1,529.00
2,500.00
13,200.00
14,100.00

About Orexo AB

View Profile
Address
Rapsgatan 7e
Uppsala UP 751 05
Sweden
Employees -
Website http://www.orexo.com
Updated 07/08/2019
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. Its pipeline comprises of Zubsolv, Abstral, Edluar, Zubsolv, OX51, OX-MP1, and OX382.